Fracture Risk Associated With Long-Term Discontinuation of Postmenopausal Osteoporosis Treatment: A French Population-Based Study Using National Claims Data (Système National des Données de Santé) - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Long-Term Cessation of Osteoporosis Therapy in Postmenopausal Women and Its Impact on Fracture Risk: Insights from a French National Claims Data Analysis
Clinical Scorecard: Long-Term Cessation of Osteoporosis Therapy in Postmenopausal Women and Its Impact on Fracture Risk: Insights from a French National Claims Data Analysis
At a Glance
Category
Detail
Condition
Postmenopausal Osteoporosis
Key Mechanisms
Inhibition of bone resorption by bisphosphonates and denosumab.
Target Population
Women aged ≥60 years with postmenopausal osteoporosis.
Care Setting
Retrospective cohort study using national health claims data.
Key Highlights
Osteoporosis affects over 200 million people globally, causing 8.9 million fractures annually.
One in three women over 50 will sustain a fragility fracture.
Long-term discontinuation of bisphosphonates may be considered after 3-5 years of treatment in low-risk patients.
Discontinuation of denosumab is not recommended due to rapid bone loss and increased fracture risk.
The study utilizes data from the French Système National de Données de Santé.
Guideline-Based Recommendations
Diagnosis
Diagnosis of osteoporosis should be based on clinical evaluation and bone mineral density assessment.
Management
Bisphosphonates are recommended as first-line therapy for postmenopausal osteoporosis.
Monitoring & Follow-up
Monitor patients for fracture risk and treatment adherence during therapy.
Risks
Long-term bisphosphonate therapy carries risks of atypical femoral fractures and osteonecrosis of the jaw.
Patient & Prescribing Data
Women aged ≥60 years initiating osteoporosis treatment with bisphosphonates or denosumab.
Patients should be evaluated for long-term therapy continuation based on fracture risk.
Clinical Best Practices
Consider long-term discontinuation of bisphosphonates in low-risk patients after appropriate treatment duration.
Avoid discontinuation of denosumab to prevent rapid bone loss.
Related Resources & Content
The Journal of Clinical Endocrinology & Metabolism, 2023 -- Efficacy of Bisphosphonate Treatment in Young Adults Experiencing Fragility Fractures: A Population-Based Cohort Analysis
The ASCO Post, 2026 -- Nonmetastatic Breast Cancer: Treatment Strategies After Denosumab Discontinuation in Patients Treated With Aromatase Inhibitors
MDSpire News, 2023 -- Fragility Fractures: Missed Opportunities in Treatment
The Journal of Clinical Endocrinology & Metabolism, 2023 -- Efficacy of Zoledronate Administered Every 5 or 10 Years for Fracture Prevention in Women Aged 50 to 60: Insights from Secondary Analyses of a Randomized Study
Project information | Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update) | Guidance | NICE, 2026
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial - PubMed, 2023
Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses - PMC, 2023
Project information | Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update) | Guidance | NICE
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial - PubMed
Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses - PMC
So get this: sodium may track with memory decline (in men), steroids might not be “immunosuppressive” in the ICU, and second pregnancies reshape the brain differently than first. Same theme: biology is less binary than we teach it.
